
In an unprecedented move, leading global pharmaceutical company Allergan appears to have handed its Orange Book-listed US patents covering …

AstraZeneca and its partner Hutchison China MedTech, also known as Chi-Med, have announced positive data for savolitinib in combination with …

Aimmune Therapeutics, a biotech company developing treatments for food allergies, announced that it has entered into a clinical trial collaboration …

The EMA received a broadside just less than two week ago from a group of researchers that had studied data …

Sanofi Aventis Nigeria plans to put together a National Diabetes Summit to address crisis in the country as five million …

Back in August, President Trump had suggested that the opioid epidemic that is ravaging the US would be declared a …

Are our pharmacovigilance measures as effective as we think? And why is it important to answer that question, especially now? …

It’s always crunch time for regulatory operations. Whether you’re managing plans and documents for an upcoming IND or producing routine product variations, …

Two clinical-stage vaccine candidates for Ebola have produced stunning results, not least because an unexpected protection emerged. The two therapies …

Janssen has announced that the FDA has approved an expanded indication for its psoriasis therapy Stelara (ustekinumab) for the treatment …

Roche had tentatively begun to re-enter the antibiotic space, but it has now signalled its growing intention to move in …

It’s been another packed week in the industry, with one of the biggest takeaways being that childhood obesity has rocketed …

The results of a study from the University of California, San Francisco will be welcomed with a certain excitement from …

Thanks to successful negotiation of a managed access agreement, NICE has announced its recommendation of Bristol-Myers Squibb’s Opdivo (nivolumab) for …

Following on from the popularity of our previous free webinar sessions, Pharmafocus is once again partnering with PrimeVigilance to bring you an overview of the EudraVigilance changes and their impact on MAHs.